Key facts
- This page summarizes Yogesh Mago's Form 4 filing for MARRONE BIO INNOVATIONS INC.
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jul 2022, 20:35.
Yogesh Mago - 12 Jul 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 12 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jul 2022, 20:35:11 UTC
- Prior SEC filing
- 05 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Linda V. Moore, as attorney in fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Yogesh Mago filed Form 4 for MARRONE BIO INNOVATIONS INC on 14 Jul 2022.
Change
- Previous filing in this sequence was filed on 05 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBII
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +321,770
- Change %
- Price
- $0.000000
- Shares after
- 321,770
- Date
- 12 Jul 2022
- Ownership
- Direct
- Footnotes
- F1, F2
MBII
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -321,770
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 12 Jul 2022
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBII
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -321,770
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 321,770
- Exercise price
- Footnotes
- F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Yogesh Mago is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
Footnote F2
The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
Footnote F3
Disposed of pursuant to the Merger Agreement in exchange for 28,315 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
Footnote F4
Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
Footnote F5
Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.